{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T02:28:43Z","timestamp":1783391323085,"version":"3.54.6"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10549-024-07604-3","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:11:04Z","timestamp":1736349064000},"page":"661-672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Shifting from axillary dissection to targeted axillary surgery after neoadjuvant treatment: the evolving management of occult breast cancer in a monoinstitutional series of 114 patients"],"prefix":"10.1007","volume":"210","author":[{"given":"Elisa","family":"Vicini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Kahler-Ribeiro-Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Polizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Petitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Pagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bagnardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Montagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Cavallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Caldarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Intra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Veronesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"issue":"1","key":"7604_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10549-004-9453-9","volume":"88","author":"V Galimberti","year":"2004","unstructured":"Galimberti V, Bassani G, Monti S et al (2004) Clinical experience with axillary presentation breast cancer. Breast Cancer Res Treat 88(1):43\u201347. https:\/\/doi.org\/10.1007\/s10549-004-9453-9","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"7604_CR2","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10549-011-1697-6","volume":"129","author":"E Montagna","year":"2011","unstructured":"Montagna E, Bagnardi V, Rotmensz N et al (2011) Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. Breast Cancer Res Treat 129(3):867\u2013875. https:\/\/doi.org\/10.1007\/s10549-011-1697-6","journal-title":"Breast Cancer Res Treat"},{"issue":"36","key":"7604_CR3","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.2217\/fon-2023-0685","volume":"19","author":"J Li","year":"2023","unstructured":"Li J, Liu G, Jia Z, Ren F, Dong D, Zhang M, Wang X, Wang Y (2023) Occult breast cancer patients with mastectomy have better prognosis than those with breast-conserving therapy. Future Oncol 19(36):2405\u20132416. https:\/\/doi.org\/10.2217\/fon-2023-0685","journal-title":"Future Oncol"},{"issue":"3","key":"7604_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","volume":"34","author":"A Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer A, Bochtler T, Pauli C, Fizazi K et al (2023) Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(3):228\u2013246. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.013","journal-title":"Ann Oncol"},{"issue":"10","key":"7604_CR5","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1245\/s10434-017-5928-x","volume":"24","author":"LK Hessler","year":"2017","unstructured":"Hessler LK, Molitoris JK, Rosenblatt PY, Bellavance EC, Nichols EM, Tkaczuk KHR, Feigenberg SJ, Bentzen SM, Kesmodel SB (2017) Factors influencing management and outcome in patients with occult breast cancer with axillary lymph node involvement: analysis of the national cancer database. Ann Surg Oncol 24(10):2907\u20132914. https:\/\/doi.org\/10.1245\/s10434-017-5928-x","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"7604_CR6","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ejso.2012.08.022","volume":"38","author":"M He","year":"2012","unstructured":"He M, Tang LC, Yu KD, Cao AY, Shen ZZ, Shao ZM, Di GH (2012) Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer. Eur J Surg Oncol 38(11):1022\u20131028. https:\/\/doi.org\/10.1016\/j.ejso.2012.08.022","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"7604_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clon.2010.10.001","volume":"23","author":"SP Masinghe","year":"2011","unstructured":"Masinghe SP, Faluyi OO, Kerr GR, Kunkler IH (2011) Breast radiotherapy for occult breast cancer with axillary nodal metastases\u2013does it reduce the local recurrence rate and increase overall survival? Clin Oncol (R Coll Radiol) 23(2):95\u2013100. https:\/\/doi.org\/10.1016\/j.clon.2010.10.001","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"6","key":"7604_CR8","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1245\/s10434-016-5104-8","volume":"23","author":"FI Macedo","year":"2016","unstructured":"Macedo FI, Eid JJ, Flynn J, Jacobs MJ, Mittal VK (2016) Optimal surgical management for occult breast carcinoma: a meta-analysis. Ann Surg Oncol 23(6):1838\u20131844. https:\/\/doi.org\/10.1245\/s10434-016-5104-8","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"7604_CR9","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1245\/s10434-017-5965-5","volume":"24","author":"DP McCartan","year":"2017","unstructured":"McCartan DP, Zabor EC, Morrow M, Van Zee KJ, El-Tamer MB (2017) Oncologic outcomes after treatment for MRI occult breast cancer (pT0N+). Ann Surg Oncol 24(11):3141\u20133147. https:\/\/doi.org\/10.1245\/s10434-017-5965-5","journal-title":"Ann Surg Oncol"},{"key":"7604_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.breast.2016.11.012","volume":"31","author":"L Schwentner","year":"2017","unstructured":"Schwentner L, Helms G, Nekljudova V et al (2017) Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy\u2014results from the multi-center SENTINA trial. Breast 31:202\u2013207. https:\/\/doi.org\/10.1016\/j.breast.2016.11.012","journal-title":"Breast"},{"issue":"3","key":"7604_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M et al (2015) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 33(3):258\u2013264. https:\/\/doi.org\/10.1200\/JCO.2014.55.7827","journal-title":"J Clin Oncol"},{"issue":"14","key":"7604_CR12","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA et al (2013) Alliance for clinical trials in oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310(14):1455\u20131461. https:\/\/doi.org\/10.1001\/jama.2013.278932","journal-title":"JAMA"},{"issue":"4","key":"7604_CR13","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","volume":"47","author":"S Kahler-Ribeiro-Fontana","year":"2021","unstructured":"Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F et al (2021) Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. Eur J Surg Oncol 47(4):804\u2013812. https:\/\/doi.org\/10.1016\/j.ejso.2020.10.014","journal-title":"Eur J Surg Oncol"},{"key":"7604_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.breast.2022.12.010","volume":"67","author":"V Galimberti","year":"2023","unstructured":"Galimberti V, Ribeiro Fontana SK, Vicini E, Morigi C, Sargenti M, Corso G, Magnoni F, Intra M, Veronesi P (2023) This house believes that: sentinel node biopsy alone is better than TAD after NACT for cN+ patients. Breast 67:21\u201325. https:\/\/doi.org\/10.1016\/j.breast.2022.12.010","journal-title":"Breast"},{"issue":"11","key":"7604_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/jamasurg.2022.3907","volume":"157","author":"JM Simons","year":"2022","unstructured":"Simons JM, van Nijnatten TJA, van der Pol CC et al (2022) Diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer. JAMA Surg 157(11):991\u2013999. https:\/\/doi.org\/10.1001\/jamasurg.2022.3907","journal-title":"JAMA Surg"},{"issue":"10","key":"7604_CR16","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34(10):1072\u20131078. https:\/\/doi.org\/10.1200\/JCO.2015.64.0094","journal-title":"J Clin Oncol"},{"issue":"3","key":"7604_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10549-022-06588-2","volume":"193","author":"J de Boniface","year":"2022","unstructured":"de Boniface J, Frisell J, K\u00fchn T et al (2022) False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy. Breast Cancer Res Treat 193(3):589\u2013595. https:\/\/doi.org\/10.1007\/s10549-022-06588-2","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"7604_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1186\/s13063-018-3021-9","volume":"19","author":"G Henke","year":"2018","unstructured":"Henke G, Knauer M, Ribi K et al (2018) Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials 19(1):667. https:\/\/doi.org\/10.1186\/s13063-018-3021-9","journal-title":"Trials"},{"key":"7604_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0578","volume":"25","author":"G Montagna","year":"2024","unstructured":"Montagna G, Mrdutt MM, Sun SX et al (2024) Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy. JAMA Oncol 25:e240578. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0578","journal-title":"JAMA Oncol"},{"issue":"14","key":"7604_CR20","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/j.ejca.2011.05.010","volume":"47","author":"SR Barton","year":"2011","unstructured":"Barton SR, Smith IE, Kirby AM, Ashley S, Walsh G, Parton M (2011) The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. Eur J Cancer 47(14):2099\u20132106. https:\/\/doi.org\/10.1016\/j.ejca.2011.05.010","journal-title":"Eur J Cancer"},{"key":"7604_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/sj.bjc.6601085","volume":"89 Suppl 1","author":"R Bugat","year":"2003","unstructured":"Bugat R, Bataillard A, Lesimple T, Voigt JJ, Culine S, Lortholary A, Merrouche Y, Ganem G, Kaminsky MC, Negrier S, Perol M, Lafor\u00eat C, Bedossa P, Bertrand G, Coindre JM, Fizazi K (2003) Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site. Br J Cancer 89 Suppl 1:59\u201366. https:\/\/doi.org\/10.1038\/sj.bjc.6601085","journal-title":"Br J Cancer"},{"issue":"10","key":"7604_CR22","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.2147\/CMAR.S169019.PMID:30349371;PMCID:PMC6188116","volume":"9","author":"LP Ge","year":"2018","unstructured":"Ge LP, Liu XY, Xiao Y, Gou ZC, Zhao S, Jiang YZ, Di GH (2018) Clinicopathological characteristics and treatment outcomes of occult breast cancer: a SEER population-based study. Cancer Manag Res 9(10):4381\u20134391. https:\/\/doi.org\/10.2147\/CMAR.S169019.PMID:30349371;PMCID:PMC6188116","journal-title":"Cancer Manag Res"},{"issue":"24","key":"7604_CR23","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.21037\/atm-22-5701","volume":"10","author":"X Man","year":"2022","unstructured":"Man X, Xu H, Wang H, Zhao J, Chen X, Yin S, Tan Q, Huang J, Sun S, Zhou D, Zheng F, Liu T, Song L, Zhang B, Li N, Li H (2022) Survival analysis and nomogram for early-stage occult breast cancer with positive lymph nodes based on the SEER database. Ann Transl Med 10(24):1351. https:\/\/doi.org\/10.21037\/atm-22-5701","journal-title":"Ann Transl Med"},{"issue":"9","key":"7604_CR24","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.3390\/jcm12093097","volume":"12","author":"J Qu","year":"2023","unstructured":"Qu J, Li C, Liu M, Wang Y, Feng Z, Li J, Wang W, Wu F, Zhang S, Zhao X (2023) Prognostic models using machine learning algorithms and treatment outcomes of occult breast cancer patients. J Clin Med 12(9):3097. https:\/\/doi.org\/10.3390\/jcm12093097","journal-title":"J Clin Med"},{"issue":"22","key":"7604_CR25","doi-asserted-by":"publisher","first-page":"6804","DOI":"10.3390\/jcm11226804","volume":"11","author":"D Zhang","year":"2022","unstructured":"Zhang D, Zhai J, Li L, Wu Y, Ma F, Xu B (2022) prognostic factors and a model for occult breast cancer: a population-based cohort study. J Clin Med 11(22):6804. https:\/\/doi.org\/10.3390\/jcm11226804","journal-title":"J Clin Med"},{"issue":"6","key":"7604_CR26","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1245\/s10434-020-08227-w","volume":"27","author":"BL Cohen","year":"2020","unstructured":"Cohen BL, Collier AL, Kelly KN, Goel N, Kesmodel SB, Yakoub D, Moller M, Avisar E, Franceschi D, Macedo FI (2020) Surgical management of the axilla in patients with occult breast cancer (cT0 N+) after neoadjuvant chemotherapy. Ann Surg Oncol 27(6):1830\u20131841. https:\/\/doi.org\/10.1245\/s10434-020-08227-w","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"7604_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1245\/s10434-014-3991-0","volume":"22","author":"NM Rueth","year":"2015","unstructured":"Rueth NM, Black DM, Limmer AR, Gabriel E, Huo L, Fornage BD, Dogan BE, Chavez-MacGregor M, Yi M, Hunt KK, Strom EA (2015) Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol 22(1):90\u201395. https:\/\/doi.org\/10.1245\/s10434-014-3991-0","journal-title":"Ann Surg Oncol"},{"key":"7604_CR28","doi-asserted-by":"publisher","DOI":"10.19187\/abc.201853138-143","author":"BS Laughlin","year":"2018","unstructured":"Laughlin BS, Ehsani S, Chalasani P, Gonzalez V (2018) Oncologic outcomes with neoadjuvant chemotherapy and breast conservation for mri occult breast cancer. Arch Breast Cancer. https:\/\/doi.org\/10.19187\/abc.201853138-143","journal-title":"Arch Breast Cancer"},{"issue":"40","key":"7604_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008200","volume":"96","author":"H Yang","year":"2017","unstructured":"Yang H, Li L, Zhang M, Zhang S, Xu S, Ma X (2017) Application of neoadjuvant chemotherapy in occult breast cancer: Five case reports. Medicine 96(40):e8200. https:\/\/doi.org\/10.1097\/MD.0000000000008200","journal-title":"Medicine"},{"issue":"2","key":"7604_CR30","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1245\/s10434-020-08863-2","volume":"28","author":"A Botty Van den Bruele","year":"2021","unstructured":"Botty Van den Bruele A, Lavery J, Plitas G, Pilewskie ML (2021) Axillary downstaging in occult primary breast cancer after neoadjuvant chemotherapy. Ann Surg Oncol 28(2):968\u2013974. https:\/\/doi.org\/10.1245\/s10434-020-08863-2","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"7604_CR31","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.surg.2023.03.020","volume":"174","author":"AC Holt","year":"2023","unstructured":"Holt AC, Haji F, McCloskey S, Baker JL (2023) De-escalation of surgery for occult breast cancer with axillary metastasis. Surgery 174(2):410\u2013412. https:\/\/doi.org\/10.1016\/j.surg.2023.03.020","journal-title":"Surgery"},{"issue":"3","key":"7604_CR32","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1016\/j.clbc.2020.08.001","volume":"21","author":"J Sun","year":"2021","unstructured":"Sun J, Henry DA, Carr MJ, Yazdankhahkenary A, Laronga C, Lee MC, Hoover SJ, Sun W, Czerniecki BJ, Khakpour N, Kiluk JV (2021) Feasibility of axillary lymph node localization and excision using radar reflector localization. Clin Breast Cancer 21(3):e189\u2013e193. https:\/\/doi.org\/10.1016\/j.clbc.2020.08.001","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"7604_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10549-021-06416-z","volume":"191","author":"JL Baker","year":"2022","unstructured":"Baker JL, Haji F, Kusske AM, Fischer CP, Hoyt AC, Thompson CK, Lee MK, Attai D, DiNome ML (2022) SAVI SCOUT\u00ae localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study. Breast Cancer Res Treat 191(1):107\u2013114. https:\/\/doi.org\/10.1007\/s10549-021-06416-z","journal-title":"Breast Cancer Res Treat"},{"key":"7604_CR34","unstructured":"https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 7 January 2025."},{"key":"7604_CR35","unstructured":"https:\/\/www.iss.it\/documents\/20126\/8403839\/LG_C0013_AIOM_Ca-mammario-precoce.pdf\/fb5df1bd-2712-9166-68e7-6e296912776e?t=1704702928747. Accessed 7 January 2025."},{"issue":"34","key":"7604_CR36","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R et al (2020) Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 38(34):3987\u20133998. https:\/\/doi.org\/10.1200\/JCO.20.02514","journal-title":"J Clin Oncol"},{"issue":"1","key":"7604_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13058-021-01453-4","volume":"23","author":"E Schaafsma","year":"2021","unstructured":"Schaafsma E, Zhang B, Schaafsma M, Tong CY, Zhang L, Cheng C (2021) Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use. Breast Cancer Res 23(1):74. https:\/\/doi.org\/10.1186\/s13058-021-01453-4","journal-title":"Breast Cancer Res"},{"issue":"24","key":"7604_CR38","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1200\/JCO.20.03613","volume":"39","author":"SM Tolaney","year":"2021","unstructured":"Tolaney SM, Garrett-Mayer E, White J et al (2021) Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0. J Clin Oncol 39(24):2720\u20132731. https:\/\/doi.org\/10.1200\/JCO.20.03613","journal-title":"J Clin Oncol"},{"key":"7604_CR39","volume-title":"The statistical analysis of failure time data","author":"JDPR Kalbfleisch","year":"1980","unstructured":"Kalbfleisch JDPR (1980) The statistical analysis of failure time data. Wiley, Hoboken"},{"key":"7604_CR40","doi-asserted-by":"publisher","first-page":"1141e54","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141e54. https:\/\/doi.org\/10.1214\/aos\/1176350951","journal-title":"Ann Stat"},{"issue":"1","key":"7604_CR41","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.1991.9.1.191","volume":"9","author":"JJ Shuster","year":"1991","unstructured":"Shuster JJ (1991) Median follow-up in clinical trials. J Clin Oncol 9(1):191\u2013192. https:\/\/doi.org\/10.1200\/JCO.1991.9.1.191","journal-title":"J Clin Oncol"},{"issue":"9","key":"7604_CR42","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(22)00482-X","volume":"23","author":"SR de Wild","year":"2022","unstructured":"de Wild SR, de Munck L, Simons JM, Verloop J, van Dalen T, Elkhuizen PHM, Houben RMA, van Leeuwen AE, Linn SC, Pijnappel RM, Poortmans PMP, Strobbe LJA, Wesseling J, Voogd AC, Boersma LJ (2022) De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010\u201303): 5-year follow-up results of a Dutch, prospective, registry study. Lancet Oncol 23(9):1201\u20131210. https:\/\/doi.org\/10.1016\/S1470-2045(22)00482-X","journal-title":"Lancet Oncol"},{"key":"7604_CR43","doi-asserted-by":"crossref","unstructured":"Mamounas E, Bandos H, White J, et al: (2023) Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: Primary outcomes of NRG Oncology\/NSABP B-51\/RTOG 1304. 2023 San Antonio Breast Cancer Symposium. Abstract GS02\u201307. Presented December 7, 2023.","DOI":"10.1158\/1538-7445.SABCS23-GS02-07"},{"issue":"1","key":"7604_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4274\/ejbh.galenos.2023.2023-10-6","volume":"20","author":"B \u00c7elik","year":"2023","unstructured":"\u00c7elik B, Boge M, Dilege E (2023) Does F-18 FDG-PET\/CT have an additional impact on axillary approach in early-stage breast cancer? Eur J Breast Health 20(1):45\u201351. https:\/\/doi.org\/10.4274\/ejbh.galenos.2023.2023-10-6","journal-title":"Eur J Breast Health"},{"issue":"30","key":"7604_CR45","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1200\/JCO.2014.57.8401","volume":"33","author":"JC Boughey","year":"2015","unstructured":"Boughey JC, Ballman KV, Hunt KK, McCall LM, Mittendorf EA, Ahrendt GM, Wilke LG, Le-Petross HT (2015) Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American college of surgeons oncology group Z1071 trial (alliance). J Clin Oncol 33(30):3386\u20133393. https:\/\/doi.org\/10.1200\/JCO.2014.57.8401","journal-title":"J Clin Oncol"},{"issue":"10","key":"7604_CR46","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3389\/fonc.2020.01420","volume":"19","author":"KY Huang","year":"2020","unstructured":"Huang KY, Zhang J, Fu WF, Lin YX, Song CG (2020) Different clinicopathological characteristics and prognostic factors for occult and non-occult breast cancer: analysis of the SEER database. Front Oncol 19(10):1420. https:\/\/doi.org\/10.3389\/fonc.2020.01420","journal-title":"Front Oncol"},{"issue":"12","key":"7604_CR47","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1245\/ASO.2005.03.520","volume":"12","author":"CL Buchanan","year":"2005","unstructured":"Buchanan CL, Morris EA, Dorn PL, Borgen PI, Van Zee KJ (2005) Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol 12(12):1045\u20131053. https:\/\/doi.org\/10.1245\/ASO.2005.03.520","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"7604_CR48","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/jpm11060465","volume":"11","author":"M Costantini","year":"2021","unstructured":"Costantini M, Montella RA, Fadda MP, Garganese G, Di Leone A, Sanchez AM, Franceschini G, Rinaldi PM (2021) Axillary nodal metastases from carcinoma of unknown primary (CUPAx): role of contrast-enhanced spectral mammography (CESM) in detecting occult breast cancer. J Pers Med 11(6):465. https:\/\/doi.org\/10.3390\/jpm11060465","journal-title":"J Pers Med"},{"key":"7604_CR49","doi-asserted-by":"publisher","unstructured":"Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017 Aug 1;28(8):1700\u20131712. https:\/\/doi.org\/10.1093\/annonc\/mdx308. Erratum in: Ann Oncol. 2018 Oct 1;29(10):2153. https:\/\/doi.org\/10.1093\/annonc\/mdx806. Erratum in: Ann Oncol. 2019 Jul 1;30(7):1181. https:\/\/doi.org\/10.1093\/annonc\/mdy537.","DOI":"10.1093\/annonc\/mdx308 10.1093\/annonc\/mdx806 10.1093\/annonc\/mdy537"},{"issue":"5","key":"7604_CR50","doi-asserted-by":"publisher","first-page":"467","DOI":"10.18632\/oncoscience.159","volume":"2","author":"M L\u00f3pez-L\u00e1zaro","year":"2015","unstructured":"L\u00f3pez-L\u00e1zaro M (2015) The migration ability of stem cells can explain the existence of cancer of unknown primary site. Rethinking Metast Oncosci 2(5):467\u2013475. https:\/\/doi.org\/10.18632\/oncoscience.159","journal-title":"Rethinking Metast Oncosci"},{"issue":"11","key":"7604_CR51","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","volume":"34","author":"G Curigliano","year":"2023","unstructured":"Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, Denkert C, Poortmans P, Weber WP, Th\u00fcrlimann B, Aebi S (2023) Understanding breast cancer complexity to improve patient outcomes: the st gallen international consensus conference for the primary therapy of individuals with early breast cancer 2023. Ann Oncol 34(11):970\u2013986. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.017","journal-title":"Ann Oncol"},{"issue":"3","key":"7604_CR52","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","volume":"34","author":"A Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer A, Bochtler T, Pauli C, Baciarello G, Delorme S, Hemminki K, Mileshkin L, Moch H, Oien K, Olivier T, Patrikidou A, Wasan H, Zarkavelis G, Pentheroudakis G, Fizazi K (2023) ESMO guidelines committee electronic address: clinicalguidelines@esmo.org. Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(3):228\u2013246. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.013","journal-title":"Ann Oncol"},{"issue":"3","key":"7604_CR53","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/SLA.0000000000003126","volume":"271","author":"S Samiei","year":"2020","unstructured":"Samiei S, van Nijnatten TJA, de Munck L, Keymeulen KBMI, Simons JM, Kooreman LFS, Siesling S, Lobbes MBI, Smidt ML (2020) Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg 271(3):574\u2013580. https:\/\/doi.org\/10.1097\/SLA.0000000000003126","journal-title":"Ann Surg"},{"issue":"12","key":"7604_CR54","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S1470-2045(22)00613-1","volume":"23","author":"HM Kuerer","year":"2022","unstructured":"Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM (2022) Exceptional responders clinical trials group eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol 23(12):1517\u20131524. https:\/\/doi.org\/10.1016\/S1470-2045(22)00613-1","journal-title":"Lancet Oncol"},{"issue":"1","key":"7604_CR55","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10549-023-06899-y","volume":"199","author":"AKE van Hemert","year":"2023","unstructured":"van Hemert AKE, van Olmen JP, Boersma LJ, Maduro JH, Russell NS, Tol J, Engelhardt EG, Rutgers EJT, Vrancken Peeters MTFD, van Duijnhoven FH (2023) De-ESCAlating radiotherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study. Breast Cancer Res Treat 199(1):81\u201389. https:\/\/doi.org\/10.1007\/s10549-023-06899-y","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7604_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.107954","volume":"50","author":"N Rocco","year":"2024","unstructured":"Rocco N, Ghilli M, Curcio A et al (2024) Is routine axillary lymph node dissection needed to tailor systemic treatments for breast cancer patients in the era of molecular oncology? A position paper of the Italian National Association of Breast Surgeons (ANISC). Eur J Surg Oncol 50(2):107954. https:\/\/doi.org\/10.1016\/j.ejso.2024.107954","journal-title":"Eur J Surg Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07604-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07604-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07604-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:46:05Z","timestamp":1743381965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07604-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7604"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07604-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"28 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is an observational retrospective study. The Clinical Trial Office has confirmed that no ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent to publish retrospective data for scientific purpose was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}